Genomic copy number imbalances associated with bone and non-bone metastasis of early-stage breast cancer

Yanhong Liu, Renke Zhou, Lars O. Baumbusch, Spyros Tsavachidis, Abenaa M. Brewster, Kim Anh Do, Aysegul Sahin, Gabriel N. Hortobagyi, Joseph H. Taube, Sendurai A. Mani, Jørgen Aarøe, Fredrik Wärnberg, Anne Lise Børresen-Dale, Gordon Mills, Patricia A. Thompson, Melissa L. Bondy

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The aim of this study is to identify and validate copy number aberrations in early-stage primary breast tumors associated with bone or non-bone metastasis. Whole-genome molecular inversion probe arrays were used to evaluate copy number imbalances (CNIs) in breast tumors from 960 early-stage patients with information about site of metastasis. The CoxBoost algorithm was used to select metastasis site-related CNIs and to fit a Cox proportional hazards model. Gains at 1q41 and 1q42.12 and losses at 1p13.3, 8p22, and Xp11.3 were significantly associated with bone metastasis. Gains at 2p11.2, 3q21.3-22.2, 3q27.1, 10q23.1, and 14q13.2-3 and loss at 7q21.11 were associated with non-bone metastasis. To examine the joint effect of CNIs and clinical predictors, patients were stratified into three risk groups (low, intermediate, and high) based on the sum of predicted linear hazard ratios. For bone metastasis, the hazard (95 % confidence interval) for the low-risk group was 0.32 (0.11-0.92) compared to the intermediate-risk group and 2.99 (1.74-5.11) for the high-risk group. For non-bone metastasis, the hazard for the low-risk group was 0.34 (0.17-0.66) and 2.33 (1.59-3.43) for the high-risk group. The prognostic value of loss at 8p22 for bone metastasis and gains at 10q23.1 for non-bone metastasis, and gain at 11q13.5 for both bone and non-bone metastases were externally validated in 335 breast tumors pooled from four independent cohorts. Distinct CNIs are independently associated with bone and non-bone metastasis for early-stage breast cancer patients across cohorts. These data warrant consideration for tailoring surveillance and management of metastasis risk.

Original languageEnglish (US)
Pages (from-to)189-201
Number of pages13
JournalBreast Cancer Research and Treatment
Volume143
Issue number1
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

Breast Neoplasms
Neoplasm Metastasis
Bone and Bones
Molecular Probes
Risk Management
Proportional Hazards Models
Genome
Confidence Intervals

Keywords

  • Bone metastasis
  • Breast cancer
  • Copy number imbalances
  • Molecular inversion probe array
  • Non-bone metastasis

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Liu, Y., Zhou, R., Baumbusch, L. O., Tsavachidis, S., Brewster, A. M., Do, K. A., ... Bondy, M. L. (2014). Genomic copy number imbalances associated with bone and non-bone metastasis of early-stage breast cancer. Breast Cancer Research and Treatment, 143(1), 189-201. https://doi.org/10.1007/s10549-013-2796-3

Genomic copy number imbalances associated with bone and non-bone metastasis of early-stage breast cancer. / Liu, Yanhong; Zhou, Renke; Baumbusch, Lars O.; Tsavachidis, Spyros; Brewster, Abenaa M.; Do, Kim Anh; Sahin, Aysegul; Hortobagyi, Gabriel N.; Taube, Joseph H.; Mani, Sendurai A.; Aarøe, Jørgen; Wärnberg, Fredrik; Børresen-Dale, Anne Lise; Mills, Gordon; Thompson, Patricia A.; Bondy, Melissa L.

In: Breast Cancer Research and Treatment, Vol. 143, No. 1, 01.01.2014, p. 189-201.

Research output: Contribution to journalArticle

Liu, Y, Zhou, R, Baumbusch, LO, Tsavachidis, S, Brewster, AM, Do, KA, Sahin, A, Hortobagyi, GN, Taube, JH, Mani, SA, Aarøe, J, Wärnberg, F, Børresen-Dale, AL, Mills, G, Thompson, PA & Bondy, ML 2014, 'Genomic copy number imbalances associated with bone and non-bone metastasis of early-stage breast cancer', Breast Cancer Research and Treatment, vol. 143, no. 1, pp. 189-201. https://doi.org/10.1007/s10549-013-2796-3
Liu, Yanhong ; Zhou, Renke ; Baumbusch, Lars O. ; Tsavachidis, Spyros ; Brewster, Abenaa M. ; Do, Kim Anh ; Sahin, Aysegul ; Hortobagyi, Gabriel N. ; Taube, Joseph H. ; Mani, Sendurai A. ; Aarøe, Jørgen ; Wärnberg, Fredrik ; Børresen-Dale, Anne Lise ; Mills, Gordon ; Thompson, Patricia A. ; Bondy, Melissa L. / Genomic copy number imbalances associated with bone and non-bone metastasis of early-stage breast cancer. In: Breast Cancer Research and Treatment. 2014 ; Vol. 143, No. 1. pp. 189-201.
@article{53134cd84a3d4598bad98f2e9b66387f,
title = "Genomic copy number imbalances associated with bone and non-bone metastasis of early-stage breast cancer",
abstract = "The aim of this study is to identify and validate copy number aberrations in early-stage primary breast tumors associated with bone or non-bone metastasis. Whole-genome molecular inversion probe arrays were used to evaluate copy number imbalances (CNIs) in breast tumors from 960 early-stage patients with information about site of metastasis. The CoxBoost algorithm was used to select metastasis site-related CNIs and to fit a Cox proportional hazards model. Gains at 1q41 and 1q42.12 and losses at 1p13.3, 8p22, and Xp11.3 were significantly associated with bone metastasis. Gains at 2p11.2, 3q21.3-22.2, 3q27.1, 10q23.1, and 14q13.2-3 and loss at 7q21.11 were associated with non-bone metastasis. To examine the joint effect of CNIs and clinical predictors, patients were stratified into three risk groups (low, intermediate, and high) based on the sum of predicted linear hazard ratios. For bone metastasis, the hazard (95 {\%} confidence interval) for the low-risk group was 0.32 (0.11-0.92) compared to the intermediate-risk group and 2.99 (1.74-5.11) for the high-risk group. For non-bone metastasis, the hazard for the low-risk group was 0.34 (0.17-0.66) and 2.33 (1.59-3.43) for the high-risk group. The prognostic value of loss at 8p22 for bone metastasis and gains at 10q23.1 for non-bone metastasis, and gain at 11q13.5 for both bone and non-bone metastases were externally validated in 335 breast tumors pooled from four independent cohorts. Distinct CNIs are independently associated with bone and non-bone metastasis for early-stage breast cancer patients across cohorts. These data warrant consideration for tailoring surveillance and management of metastasis risk.",
keywords = "Bone metastasis, Breast cancer, Copy number imbalances, Molecular inversion probe array, Non-bone metastasis",
author = "Yanhong Liu and Renke Zhou and Baumbusch, {Lars O.} and Spyros Tsavachidis and Brewster, {Abenaa M.} and Do, {Kim Anh} and Aysegul Sahin and Hortobagyi, {Gabriel N.} and Taube, {Joseph H.} and Mani, {Sendurai A.} and J{\o}rgen Aar{\o}e and Fredrik W{\"a}rnberg and B{\o}rresen-Dale, {Anne Lise} and Gordon Mills and Thompson, {Patricia A.} and Bondy, {Melissa L.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1007/s10549-013-2796-3",
language = "English (US)",
volume = "143",
pages = "189--201",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - Genomic copy number imbalances associated with bone and non-bone metastasis of early-stage breast cancer

AU - Liu, Yanhong

AU - Zhou, Renke

AU - Baumbusch, Lars O.

AU - Tsavachidis, Spyros

AU - Brewster, Abenaa M.

AU - Do, Kim Anh

AU - Sahin, Aysegul

AU - Hortobagyi, Gabriel N.

AU - Taube, Joseph H.

AU - Mani, Sendurai A.

AU - Aarøe, Jørgen

AU - Wärnberg, Fredrik

AU - Børresen-Dale, Anne Lise

AU - Mills, Gordon

AU - Thompson, Patricia A.

AU - Bondy, Melissa L.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - The aim of this study is to identify and validate copy number aberrations in early-stage primary breast tumors associated with bone or non-bone metastasis. Whole-genome molecular inversion probe arrays were used to evaluate copy number imbalances (CNIs) in breast tumors from 960 early-stage patients with information about site of metastasis. The CoxBoost algorithm was used to select metastasis site-related CNIs and to fit a Cox proportional hazards model. Gains at 1q41 and 1q42.12 and losses at 1p13.3, 8p22, and Xp11.3 were significantly associated with bone metastasis. Gains at 2p11.2, 3q21.3-22.2, 3q27.1, 10q23.1, and 14q13.2-3 and loss at 7q21.11 were associated with non-bone metastasis. To examine the joint effect of CNIs and clinical predictors, patients were stratified into three risk groups (low, intermediate, and high) based on the sum of predicted linear hazard ratios. For bone metastasis, the hazard (95 % confidence interval) for the low-risk group was 0.32 (0.11-0.92) compared to the intermediate-risk group and 2.99 (1.74-5.11) for the high-risk group. For non-bone metastasis, the hazard for the low-risk group was 0.34 (0.17-0.66) and 2.33 (1.59-3.43) for the high-risk group. The prognostic value of loss at 8p22 for bone metastasis and gains at 10q23.1 for non-bone metastasis, and gain at 11q13.5 for both bone and non-bone metastases were externally validated in 335 breast tumors pooled from four independent cohorts. Distinct CNIs are independently associated with bone and non-bone metastasis for early-stage breast cancer patients across cohorts. These data warrant consideration for tailoring surveillance and management of metastasis risk.

AB - The aim of this study is to identify and validate copy number aberrations in early-stage primary breast tumors associated with bone or non-bone metastasis. Whole-genome molecular inversion probe arrays were used to evaluate copy number imbalances (CNIs) in breast tumors from 960 early-stage patients with information about site of metastasis. The CoxBoost algorithm was used to select metastasis site-related CNIs and to fit a Cox proportional hazards model. Gains at 1q41 and 1q42.12 and losses at 1p13.3, 8p22, and Xp11.3 were significantly associated with bone metastasis. Gains at 2p11.2, 3q21.3-22.2, 3q27.1, 10q23.1, and 14q13.2-3 and loss at 7q21.11 were associated with non-bone metastasis. To examine the joint effect of CNIs and clinical predictors, patients were stratified into three risk groups (low, intermediate, and high) based on the sum of predicted linear hazard ratios. For bone metastasis, the hazard (95 % confidence interval) for the low-risk group was 0.32 (0.11-0.92) compared to the intermediate-risk group and 2.99 (1.74-5.11) for the high-risk group. For non-bone metastasis, the hazard for the low-risk group was 0.34 (0.17-0.66) and 2.33 (1.59-3.43) for the high-risk group. The prognostic value of loss at 8p22 for bone metastasis and gains at 10q23.1 for non-bone metastasis, and gain at 11q13.5 for both bone and non-bone metastases were externally validated in 335 breast tumors pooled from four independent cohorts. Distinct CNIs are independently associated with bone and non-bone metastasis for early-stage breast cancer patients across cohorts. These data warrant consideration for tailoring surveillance and management of metastasis risk.

KW - Bone metastasis

KW - Breast cancer

KW - Copy number imbalances

KW - Molecular inversion probe array

KW - Non-bone metastasis

UR - http://www.scopus.com/inward/record.url?scp=84892830266&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892830266&partnerID=8YFLogxK

U2 - 10.1007/s10549-013-2796-3

DO - 10.1007/s10549-013-2796-3

M3 - Article

VL - 143

SP - 189

EP - 201

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 1

ER -